Target Price | $35.75 |
Price | $10.57 |
Potential |
238.22%
register free of charge
|
Number of Estimates | 12 |
12 Analysts have issued a price target Syndax Pharmaceuticals Inc 2026 .
The average Syndax Pharmaceuticals Inc target price is $35.75.
This is
238.22%
register free of charge
$51.00
382.50%
register free of charge
$17.00
60.83%
register free of charge
|
|
A rating was issued by 13 analysts: 12 Analysts recommend Syndax Pharmaceuticals Inc to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Syndax Pharmaceuticals Inc stock has an average upside potential 2026 of
238.22%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 23.68 | 115.00 |
385.64% | ||
EBITDA Margin | -1,434.38% | -303.99% |
78.81% | ||
Net Margin | -1,351.80% | -283.69% |
79.01% |
12 Analysts have issued a sales forecast Syndax Pharmaceuticals Inc 2025 . The average Syndax Pharmaceuticals Inc sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Syndax Pharmaceuticals Inc EBITDA forecast 2025. The average Syndax Pharmaceuticals Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
12 Syndax Pharmaceuticals Inc Analysts have issued a net profit forecast 2025. The average Syndax Pharmaceuticals Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -3.72 | -3.79 |
24.83% | 1.88% | |
P/E | negative | |
EV/Sales | 6.46 |
12 Analysts have issued a Syndax Pharmaceuticals Inc forecast for earnings per share. The average Syndax Pharmaceuticals Inc EPS is
This results in the following potential growth metrics and future valuations:
Syndax Pharmaceuticals Inc...
Analyst | Rating | Action | Date |
---|---|---|---|
Scotiabank |
Locked
➜
Locked
|
Locked | May 06 2025 |
Guggenheim |
Locked
➜
Locked
|
Locked | May 06 2025 |
JP Morgan |
Locked
➜
Locked
|
Locked | Mar 20 2025 |
Citigroup |
Locked
➜
Locked
|
Locked | Mar 04 2025 |
JP Morgan |
Locked
➜
Locked
|
Locked | Mar 04 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 04 2025 |
Scotiabank |
Locked
➜
Locked
|
Locked | Jan 08 2025 |
Analyst Rating | Date |
---|---|
Locked
Scotiabank:
Locked
➜
Locked
|
May 06 2025 |
Locked
Guggenheim:
Locked
➜
Locked
|
May 06 2025 |
Locked
JP Morgan:
Locked
➜
Locked
|
Mar 20 2025 |
Locked
Citigroup:
Locked
➜
Locked
|
Mar 04 2025 |
Locked
JP Morgan:
Locked
➜
Locked
|
Mar 04 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 04 2025 |
Locked
Scotiabank:
Locked
➜
Locked
|
Jan 08 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.